In the ongoing randomized phase III CROWN study, it was shown that a decrease in the mean variant allele fraction (VAF) of ALK alterations (fusions and/or mutations) 4 weeks after lorlatinib in ALK-positive NSCLC, previously untreated, may be associated with better responses and longer PFS. The gene discussed is ALK; the disease is non-small cell lung carcinoma.